These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 33248413)
1. LncRNA PDCD4-AS1 alleviates triple negative breast cancer by increasing expression of IQGAP2 via miR-10b-5p. Wang D; Wang Z; Zhang L; Sun S Transl Oncol; 2021 Jan; 14(1):100958. PubMed ID: 33248413 [TBL] [Abstract][Full Text] [Related]
2. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy. Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923 [TBL] [Abstract][Full Text] [Related]
3. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis. Han C; Fu Y; Zeng N; Yin J; Li Q Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085 [TBL] [Abstract][Full Text] [Related]
4. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis. Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083 [TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA Tang L; Chen Y; Tang X; Wei D; Xu X; Yan F J Cancer; 2020; 11(2):311-323. PubMed ID: 31897227 [No Abstract] [Full Text] [Related]
6. LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer. Jiang Z; Li L; Hou Z; Liu W; Wang H; Zhou T; Li Y; Chen S Cell Signal; 2020 Feb; 66():109483. PubMed ID: 31760170 [TBL] [Abstract][Full Text] [Related]
7. GATA1-Activated HNF1A-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-32-5p to Upregulate RNF38. Yang J; Niu H; Chen X Cancer Manag Res; 2021; 13():1357-1369. PubMed ID: 33603481 [TBL] [Abstract][Full Text] [Related]
8. LncRNA SLC16A1-AS1 regulates the miR-182/PDCD4 axis and inhibits the triple-negative breast cancer cell cycle. Jiang B; Liu Q; Gai J; Guan J; Li Q Immunopharmacol Immunotoxicol; 2022 Aug; 44(4):534-540. PubMed ID: 35316129 [TBL] [Abstract][Full Text] [Related]
9. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54. Liu B; Yao P; Xiao F; Guo J; Wu L; Yang Y J Transl Med; 2021 Aug; 19(1):333. PubMed ID: 34353336 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway. Chen Y; Gao H; Li Y Mol Cell Endocrinol; 2020 Jan; 500():110634. PubMed ID: 31678422 [TBL] [Abstract][Full Text] [Related]
11. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition. Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486 [TBL] [Abstract][Full Text] [Related]
12. LRRC75A-AS1 targets miR-199b-5p/PDCD4 axis to repress multiple myeloma. Pang Q; Wang Y; Bi D; Lu H Cancer Biol Ther; 2020 Nov; 21(11):1051-1059. PubMed ID: 33131397 [TBL] [Abstract][Full Text] [Related]
13. LncRNA MCM3AP-AS1 promotes chemoresistance in triple-negative breast cancer through the miR-524-5p/RBM39 axis. Wang Y; Wang X; Sun H; Zhang Z; Gu J Mol Cell Biochem; 2024 Mar; ():. PubMed ID: 38472681 [TBL] [Abstract][Full Text] [Related]
14. lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p. Peng Y; Huang X; Wang H BMC Mol Cell Biol; 2022 Jul; 23(1):34. PubMed ID: 35896973 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway. Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958 [TBL] [Abstract][Full Text] [Related]
16. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p. Hou S; Lin Q; Guan F; Lin C J Cell Biochem; 2018 Nov; 119(10):8304-8316. PubMed ID: 29893424 [TBL] [Abstract][Full Text] [Related]
17. lncRNA MIR503HG inhibits cell proliferation and promotes apoptosis in TNBC cells via the miR-224-5p/HOXA9 axis. Wang SM; Pang J; Zhang KJ; Zhou ZY; Chen FY Mol Ther Oncolytics; 2021 Jun; 21():62-73. PubMed ID: 33869743 [TBL] [Abstract][Full Text] [Related]
18. LRP11-AS1 promotes the proliferation and migration of triple negative breast cancer cells via the miR-149-3p/NRP2 axis. Li P; Zeng Y; Chen Y; Huang P; Chen X; Zheng W Cancer Cell Int; 2022 Mar; 22(1):116. PubMed ID: 35279146 [TBL] [Abstract][Full Text] [Related]
19. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164 [TBL] [Abstract][Full Text] [Related]
20. LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. Xing L; Tang X; Wu K; Huang X; Yi Y; Huan J Aging (Albany NY); 2020 Dec; 13(1):424-436. PubMed ID: 33290256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]